Table 1 Summary of study design
Investigator | Year | Location | Pop. Characteristics | Publication type | Study Design | N | Median Age | Treatment technique | QOL tool | Assessment Timeline |
|---|---|---|---|---|---|---|---|---|---|---|
Thibault [21] | 2014 | Canada | Mets (30) | Conference Abstract | Prospective Longitudinal Cohort | 30 | 65 (40–88) | SBRT 30-60Gy, 3-6# | QLQ-C15PAL QLQ-LM21 | Baseline, 1, 6, 12 weeks post treatment |
Shun [22] | 2008 | Taiwan | HCC (99) | Journal article | Prospective Longitudinal Cohort | 99 | 62.42 (12.6) | SRT - Mean dose 42.6Gy | FLIC-QOL | 1 week pre treatment, weekly x6 weeks during |
Mendez Romero [20] | 2008 | Netherlands | Mets (19) HCC (9) | Journal article | Prospective Longitudinal Cohort | 25 | 68 (37–81) | SBRT 3x12.5Gy 5x5Gy 3x10Gy | EQ-5D EQ-5D VAS QLQ C-30 | 1 month pre + 1, 3, 6 months post treatment |
Klein [18] | 2015 | Canada | Mets (86) HCC (98) IHC (21) | Journal article | Prospective Longitudinal Cohort | 205 | 67 (30–90) | Image guided SBRT 24–60 GY/6# | QLQ-C30 FACT-Hep | Baseline and 1,3,6,12 months post treatment |
Law [19] | 2012 | Hong Kong | HCC (33) | Journal article | Prospective Longitudinal Cohort | 33 | 69 (47–89) | Highly-conformal RT 55GY/10# | FACT-Hep | Baseline, 3, 6 months |